<DOC>
	<DOCNO>NCT02047305</DOCNO>
	<brief_summary>Patients MGIN , HGIN flat-type early SCCA esophagus treat 3 month interval Radiofrequency Ablation ( RFA ) complete eradication ( CR : MGIN bad biopsy ) achieve . All patient undergo endoscopy 12 month baseline , patient CR undergo annual endoscopy biopsy 5 year .</brief_summary>
	<brief_title>Radiofrequency Ablation Patients With Esophageal Squamous Cell Neoplasia</brief_title>
	<detailed_description>A patient population histopathological diagnosis moderate-grade intra-epithelial neoplasia ( MGIN ) , high-grade intra-epithelial neoplasia ( HGIN ) and/or early flat-type SCCA esophagus , lesion measure 3 12cm length , treat radiofrequency ablation ( RFA ) use HALO ablation system . Additional RFA session perform 3 month interval complete response ( CR ; MGIN bad biopsy ) achieve . All patient undergo endoscopy 12 month baseline . Patients CR 12 month followed-up 5 year annual endoscopy biopsy , additional treatment necessary . Patients CR 12 month consider failure .</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<criteria>1 . Subject 1880 year age , inclusive 2 . Subject meet least one follow inclusion criterion : 1 . Within last 3 month , subject demonstrate new diagnosis reconfirm diagnosis squamous MGIN and/or HGIN esophagus , ... 2. within last 3 month , subject demonstrate new diagnosis flattype ( type 0IIb ) SCCA ( G1/G2 ) 3 . On endoscopic examination , subject least one USL measure least 3 cm least one dimension MGIN worse ( MGIN+ ) biopsy 4 . The maximum allowable linear length `` USLbearing esophagus '' 12 cm 5 . Baseline EUS ( patient ) show exclusionary finding trial 6 . CT scan chest upper third abdomen ( HGIN SCCA patient ) show exclusionary finding trial 7 . Subject pregnant plan become pregnant ensue 12 month ( confirmation nonpregnant status woman childbearing age ability require urine blood test ) 8 . Subject eligible treatment followup endoscopy biopsy require protocol 9 . The subject willing provide write , inform consent participate clinical study understand responsibility trial participation Eligibility CRF . 1 . Esophageal stricture prevent passage therapeutic endoscope 2 . Any prior endoscopic resection 3 . Any esophageal dilation past 12 month 4 . Any history nonsquamous cell cancer esophagus , history squamous cell cancer esophagus ( stage ) prior 3 month screen trial 5 . Any N M positive status , patient present diagnosis esophageal SCCA 6 . Any previous ablative therapy within esophagus ( photodynamic therapy , multipolar electrical coagulation , argon plasma coagulation , laser treatment , ) radiation therapy esophagus . 7 . Any previous esophageal surgery , except fundoplication without complication ( i.e . slippage , dysphagia , etc ) 8 . Evidence esophageal varix detect within last 6 month initial RFA procedure 9 . Evidence eosinophilic esophagitis endoscopy and/or histology 10 . Report uncontrolled coagulopathy international normalize ratio ( INR ) &gt; 2 platelet count &lt; 75,000 platelet per ÂµL ( note : complete blood count require subject study ) 11 . Subject use aspirin , clopidogrel , nonsteroidal antiinflammatory drug discontinue 7 day therapeutic session 12 . Subject known history unresolved drug alcohol dependency would limit ability comprehend follow instruction relate informed consent , posttreatment instruction , followup guideline 13 . Subject implantable pacing device ( example ; AICD , neurostimulator , cardiac pacemaker ) receive clearance enrollment study specialist responsible pacing device 14 . Subject suffers psychiatric illness deem investigator inability comply protocol 15 . Subject life expectancy le 2 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>ESCN</keyword>
	<keyword>RFA</keyword>
</DOC>